GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shandong Weigao Group Medical Polymer Co Ltd (HKSE:01066) » Definitions » Piotroski F-Score

Shandong Weigao Group Medical Polymer Co (HKSE:01066) Piotroski F-Score : 3 (As of Apr. 25, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Shandong Weigao Group Medical Polymer Co Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shandong Weigao Group Medical Polymer Co has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Shandong Weigao Group Medical Polymer Co's Piotroski F-Score or its related term are showing as below:

HKSE:01066' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 6   Max: 7
Current: 3

During the past 13 years, the highest Piotroski F-Score of Shandong Weigao Group Medical Polymer Co was 7. The lowest was 3. And the median was 6.


Shandong Weigao Group Medical Polymer Co Piotroski F-Score Historical Data

The historical data trend for Shandong Weigao Group Medical Polymer Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Weigao Group Medical Polymer Co Piotroski F-Score Chart

Shandong Weigao Group Medical Polymer Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 7.00 6.00 3.00 -

Shandong Weigao Group Medical Polymer Co Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 - 3.00 - -

Competitive Comparison of Shandong Weigao Group Medical Polymer Co's Piotroski F-Score

For the Medical Instruments & Supplies subindustry, Shandong Weigao Group Medical Polymer Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shandong Weigao Group Medical Polymer Co's Piotroski F-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Shandong Weigao Group Medical Polymer Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shandong Weigao Group Medical Polymer Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec22) TTM:Last Year (Dec21) TTM:
Net Income was HK$3,041 Mil.
Cash Flow from Operations was HK$2,473 Mil.
Revenue was HK$15,209 Mil.
Gross Profit was HK$7,943 Mil.
Average Total Assets from the begining of this year (Dec21)
to the end of this year (Dec22) was (37441.466 + 37300.884) / 2 = HK$37371.175 Mil.
Total Assets at the begining of this year (Dec21) was HK$37,441 Mil.
Long-Term Debt & Capital Lease Obligation was HK$3,910 Mil.
Total Current Assets was HK$20,422 Mil.
Total Current Liabilities was HK$6,706 Mil.
Net Income was HK$2,787 Mil.

Revenue was HK$16,174 Mil.
Gross Profit was HK$9,003 Mil.
Average Total Assets from the begining of last year (Dec20)
to the end of last year (Dec21) was (33141.991 + 37441.466) / 2 = HK$35291.7285 Mil.
Total Assets at the begining of last year (Dec20) was HK$33,142 Mil.
Long-Term Debt & Capital Lease Obligation was HK$4,302 Mil.
Total Current Assets was HK$19,910 Mil.
Total Current Liabilities was HK$6,340 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shandong Weigao Group Medical Polymer Co's current Net Income (TTM) was 3,041. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shandong Weigao Group Medical Polymer Co's current Cash Flow from Operations (TTM) was 2,473. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec21)
=3041.159/37441.466
=0.08122436

ROA (Last Year)=Net Income/Total Assets (Dec20)
=2786.801/33141.991
=0.08408671

Shandong Weigao Group Medical Polymer Co's return on assets of this year was 0.08122436. Shandong Weigao Group Medical Polymer Co's return on assets of last year was 0.08408671. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shandong Weigao Group Medical Polymer Co's current Net Income (TTM) was 3,041. Shandong Weigao Group Medical Polymer Co's current Cash Flow from Operations (TTM) was 2,473. ==> 2,473 <= 3,041 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=3909.915/37371.175
=0.10462382

Gearing (Last Year: Dec21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec20 to Dec21
=4301.669/35291.7285
=0.12188887

Shandong Weigao Group Medical Polymer Co's gearing of this year was 0.10462382. Shandong Weigao Group Medical Polymer Co's gearing of last year was 0.12188887. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec22)=Total Current Assets/Total Current Liabilities
=20421.92/6706.048
=3.04529881

Current Ratio (Last Year: Dec21)=Total Current Assets/Total Current Liabilities
=19909.617/6339.969
=3.14033349

Shandong Weigao Group Medical Polymer Co's current ratio of this year was 3.04529881. Shandong Weigao Group Medical Polymer Co's current ratio of last year was 3.14033349. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shandong Weigao Group Medical Polymer Co's number of shares in issue this year was 4526.649. Shandong Weigao Group Medical Polymer Co's number of shares in issue last year was 4516.323. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=7943.283/15208.546
=0.52229076

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=9003.378/16173.918
=0.5566603

Shandong Weigao Group Medical Polymer Co's gross margin of this year was 0.52229076. Shandong Weigao Group Medical Polymer Co's gross margin of last year was 0.5566603. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec21)
=15208.546/37441.466
=0.40619526

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec20)
=16173.918/33141.991
=0.4880189

Shandong Weigao Group Medical Polymer Co's asset turnover of this year was 0.40619526. Shandong Weigao Group Medical Polymer Co's asset turnover of last year was 0.4880189. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+0+0+1+0+0+0+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shandong Weigao Group Medical Polymer Co has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Shandong Weigao Group Medical Polymer Co  (HKSE:01066) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shandong Weigao Group Medical Polymer Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Shandong Weigao Group Medical Polymer Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shandong Weigao Group Medical Polymer Co (HKSE:01066) Business Description

Traded in Other Exchanges
Address
No.1, Weigao Road, Torch Hi-tech Science Park, Shandong Province, Weihai, CHN
Shandong Weigao Group Medical Polymer Co Ltd functions in the healthcare sector in China. Its business mainly involves the research and development, production, and sale of single-use medical device products. The company's segments include Medical device products, Orthopaedic products, Interventional products, Pharma packaging products, Blood management products, and others. The company's products comprise consumables including infusion sets, syringes, medical needles, blood bags, prefilled syringes, wound management, blood sampling products; orthopedic materials, and blood purification consumables and equipment. The company operates in the People's Republic of China, the United States, Europe, the Middle East, and Africa, Asia, and others.

Shandong Weigao Group Medical Polymer Co (HKSE:01066) Headlines

No Headlines